Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients

NCT ID: NCT01819441

Last Updated: 2015-10-23

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 1200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-05-31
• Study Completion Date: 2016-12-31

Brief Summary

A. the controlling of the blood pressure, especially the variation of blood pressure, can slow down the development of the small vessel disease.

B intensive BP control is more effective than normal control of blood pressure in slowing down the small vessel disease.

C drugs of Calcium Channel Blocker(CCB) and Angiotensin-Converting Enzyme Inhibitor(ACEI) have no significant difference in lowing the blood pressure and variability of blood pressure

Detailed Description

The selected patients were diagnosis of stroke caused by small vessel disease due to hypertension recently.

The patients had been divided into two groups by random principle and given ACEI or CCB separately for treatment. At the same time, given intensive or regular controlling of the blood pressure by stratified random. In the regular controlling group, the BP should be in the range of 130-139 mmHg and in the intensive controlling group, the BP should be below 130 mmHg. To the acute ischemic stroke patients who were accord with the lacunar infarction syndrome, it is rule to do the examination for exclusive selection of exclusion of hemodynamic dysfunction due to the artery stenosis ( stenosis >50%, the examination of intracranial artery was by the methods of Transcranial Doppler (TCD)/Magnetic Resonance Angiography(MRA)/Computed Tomographic Angiography(CTA)/Digital Subtraction Angiography(DSA), the examination of carotid artery was by the methods of colorful ultrasound / MRA/ CTA/ DSA ) at the baseline.

It should be proved of lacunar infarction by brain imaging. All patients had a MRI scan at the baseline and the beginning of the research, including T1-Weighted Imaging(T1W1),T2-Weighted Imaging(T2WI), T2-FLAIR, Diffusion-Weighted Imaging(DWI), Gradient-Recalled Echo(GRE) T2*, the Perfusion-Weighted Imaging(PWI) would complete conditionally (100 cases). The details should be followed by the instruction in the appendix.

Research about the variability of blood pressure: all patients show complete the examination of 24-hour blood-pressure monitor (at the baseline, the first month after the beginning, every three months and the end of the research), complete the head-up tilt test if conditionally ( at the baseline, each 3 months later and the end of the research ) The automatic regulation function of the small vessel should be evaluated if conditionally (the C02 reaction, TCD head-up tilt) and also the function of endothelium-derived relaxing of the brachial artery (at the baseline, each 3 months later and the end of the research) The reservation of the blood was for further research on genetic study.

Conditions

Cerebral Small Vessel Diseases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Normal Azelnidipine/Perindopril

Systole blood pressure controlled between 130 mmHg\~140 mmHg(with or without hydrochlorothiazide).

Group Type: SHAM_COMPARATOR

Azelnidipine

Intervention Type: DRUG

8mg or 16mg

Perindopril

Intervention Type: DRUG

4mg or 8mg

hydrochlorothiazide

Intervention Type: DRUG

12.5mg or 25mg

Intensive Azelnidipine/Perindopril

Systole blood pressure controlled below 130 mmHg(with or without hydrochlorothiazide).

Group Type: EXPERIMENTAL

Azelnidipine

Intervention Type: DRUG

8mg or 16mg

Perindopril

Intervention Type: DRUG

4mg or 8mg

hydrochlorothiazide

Intervention Type: DRUG

12.5mg or 25mg

Interventions

Azelnidipine

8mg or 16mg

Intervention Type: DRUG

Perindopril

4mg or 8mg

Intervention Type: DRUG

hydrochlorothiazide

12.5mg or 25mg

Intervention Type: DRUG

Other Intervention Names

BeiQi; YiTai

Eligibility Criteria

Inclusion Criteria

• Cerebral infarction within 10 days to 6 months.
• Clinical manifestation represented as lacunar infarction syndrome; without aphasia or disturbance of consciousness.
• Mini-Mental State Examination(MMSE)>24 and modified Rankin Score(mRS)≤3.
• History of hypertension, and need to be treated with drugs; patient who had been diagnosis hypertension or the first time with the diagnosis of this disease after the guideline of China 2010 (measurement of the BP in the seated posture of the up arm after having a rest for 5 minutes and was taken for three times and calculated the average result, make sure the difference of BP between right and left arm are not beyond the criteria of 20 mmHg and the right arm for consistence. The patients have different BP between both sides which the difference beyond 20 mmHg need to exam for the stenosis of subclavian artery.
• MRI confirm the lesion for lacunar infarction and be responsible for the clinical symptom located in the region of perforating artery and the diameter of the lesion is less than 20mm.
• The examinations of carotid artery and intracranial artery have excluded hemodynamic abnormalities due to artery stenosis ( stenosis >50%, the examination of intracranial artery was by the methods of TCD/ MRA/ CTA/ DSA, the examination of carotid artery was by the methods of colorful ultrasound / MRA/ CTA/ DSA ). The combination of thickness Intima media or plaque of the carotid artery without the hemodynamic dysfunction can be enrolled in this research.
• Informed consent was signed.

Exclusion Criteria

• Hypertension diffcult to control, instantly over 220/ 120 mmHg.
• History of atrial fibrillation (Paroxysmal or sustained).
• History of heart infarction within 6 months.
• Stenosis above 50% or hemodynamic dysfunction in carotid and intracranial artery after examination.
• Unknown caused of brain infarction, like dissection vascular, Moyamoya disease, vasculitis, hereditary small angiopathy ( eg,Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leucoencephalopathy(CADASIL), FABRY, mitochondrial encephalopathy).
• Severe liver and renal disease. the definition of sever liver disease was Alanine aminotransferase(ALT) or Aspartate aminotransferase(AST) 4 times than the normal level, or the total bilirubin above 20 mmol/L, or cirrhosis. the definition of sever renal disease was stenosis of renal artery and dysfunction of renal (clearance rate of creatinine <60ml/min or serum creatinine >265mmol/L).
• History of hemorrhage.
• Active bleeding disease or clear coagulation disorders.
• Malignant neoplasm.
• Pregnancy.
• Severe organic diseases, expected lifetime was shorter than 2 years.
• Conditions contraindicated for CCB or ACEI, such as hyperpotassaemia (serum potassium >5.5mmol/L) or have the evidence proved allergic to both drugs.
• Eenrolled in another clinical trial in 30 days.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Yining Huang

OTHER

Sponsor Role: lead

Responsible Party

Yining Huang

chairman

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Yining Huang, M.D.

Role: PRINCIPAL_INVESTIGATOR

Peking University First Hospital

Locations

Peking University First Hospital

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Peking University First Hospital

Role: CONTACT

Facility Contacts

Yining Huang

Role: primary

ynhuang@sina.com

Other Identifiers

APPROVE

Identifier Type: REGISTRY

Identifier Source: secondary_id

Peking University

Identifier Type: -

Identifier Source: org_study_id